Work

A Phase 3, multicenter, open-label, switchover trial to assess the safety and efficacy of taliglucerase alfa, a plant cell-expressed recombinant human glucocerebrosidase, in adult and pediatric patients with Gaucher disease previously treated with imiglucerase

Year: 2014

Type: article

Study design: Clinical Trial

Source: Blood Cells Molecules and Diseases

DOI: 10.1016/j.bcmd.2014.05.004

Authors: Gregory M. Pastores, Milan Petakov, Pilar Giraldo, Hanna Rosenbaum, Jeffrey Szer, Patrick B. Deegan, Dominick J. Amato, Eugen Mengel, Ee Shien Tan, Raul Chertkoff, Einat Brill-Almon, Ari Zimran

Institutions: NYU Langone Health, New York University, University of Belgrade, Univerzitetski Klinički Centar Srbije, Hospital Universitario Miguel Servet, Rambam Health Care Campus, The Royal Melbourne Hospital, University of Cambridge, Addenbrooke's Hospital, Mount Sinai Hospital, Johannes Gutenberg University Mainz, KK Women's and Children's Hospital, Protalix BioTherapeutics (Israel), Shaare Zedek Medical Center, Bikur Cholim Hospital

Language: English

Topic: Lysosomal Storage Disorders Research

Subfield: Genetics (clinical)

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: Pfizer

OpenAlex ID: W2021531902

FWCI: 7.343

Cites: 8

Cited by: 61

Related to: 10